Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer
Conclusions: Biosimilar trastuzumab demonstrated similar safety and effectiveness to Herceptin. The findings can help improve confidence in and use of biosimilars and demonstrate the value of real-world evidence generation for supporting biosimilar implementations and reassessments.PMID:38534957 | PMC:PMC10969053 | DOI:10.3390/curroncol31030124
Source: Current Oncology - Category: Cancer & Oncology Authors: Caroline Mu ñoz Xiaochen Tai Jessica Arias Andrea Eisen Munaza Chaudhry Scott Gavura Kelvin K W Chan Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Congestive Heart Failure | Emergency Medicine | Heart | Heart Failure | HER2 | Herceptin | History of Medicine | Neoadjuvant Therapy | Study